key: cord-0718163-vhp45433
authors: Li, Na; Rana, Tariq
title: Detection of N6-methyladenosine in SARS-CoV-2 RNA by methylated RNA immunoprecipitation sequencing (MeRIP-Seq)
date: 2021-12-08
journal: STAR Protoc
DOI: 10.1016/j.xpro.2021.101067
sha: 246a5573fafeddc3df1b6aab1bfd66a24b401ff9
doc_id: 718163
cord_uid: vhp45433

N 6 -methylation of adenosine (m6A) is the most abundant internal mRNA modification and is an important post-transcriptional regulator of gene expression. Here, we describe a protocol for methylated RNA immunoprecipitation sequencing (MeRIP-Seq) to detect and quantify m6A-modifications in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. The protocol is optimized for low viral RNA levels and is readily adaptable for other applications.

We describe here the protocol for MeRIP-Seq analysis of SARS-CoV-2 viral RNA extracted from infected Caco-2, a human colorectal adenocarcinoma cell line, and culture supernatants. However, we have also used this protocol for analysis of viral RNA extracted from infected Vero cells, and for analysis of mammalian RNA extracted from mouse tumor tissues (Li et al., 2020) . The protocol is applied here to SARS-CoV-2 infected Caco-2 cells that harbor shRNA targeting the methyltransferase METTL3 (shMETTL3) or control shRNA (shControl), thus providing an example of normal and experimentally reduced m6A-modified RNA. We describe the selection of stable shRNA-expressing Caco-2 cell lines and SARS-CoV-2 infection first, followed by a detailed step-by-step description of MeRIP-Seq and analysis. All the lentivirus and SARS-CoV-2 infection experiments should be performed after obtaining approvals from Institutional Biosafety Committee. Key resources table REAGENT (Langmead and Salzberg, 2012) http://bowtiebio.sourceforge.net/bo wtie2/index.shtml Samtools (Li et al., 2009) http://samtools.sourcef orge.net/ STAR (Dobin et al., 2013) https://github.com/alex dobin/STAR MACS2 (Zhang et al., 2008) https://github.com/mac s3-project/MACS m6A Viewer (Antanaviciute et al., 2017) http://dna2.leeds.ac.uk/ m6a/ Cutadapt (Martin, 2011) https://cutadapt.readth edocs.io/en/stable/ Integrative Genomics Viewer (James T. Robinson, 2020; Robinson et al., 2017; Robinson et al., 2011; Thorvaldsdottir et al., 2013) Step-by-step method details J o u r n a l P r e -p r o o f a. The day before transduction, seed 5×10 5 Caco-2 cells in high-glucose MEM supplemented with 20% fetal bovine serum, MEM NEAA and 50 U/mL penicillin-streptomycin and seed in a 6-well plate at a density sufficient to reach ~50% confluence ~24 h later. b. Remove the supernatant from the seeded Caco-2 cells, add 800 μl shControl or shMETTL3 lentivirus in 1.2ml medium, and then add Polybrene to a final concentration of 8 µg/mL.

Note: The precise volume for added virus will be based on the lentiviral titer (see Troubleshooting Problem 1).

c. Spin the plates at 485×g for 2 h at 25°C. d. Incubate the plates at 37°C for 12 h, exchange the transduction medium for fresh MEM medium, incubate at 37°C for 48 h, and then start selection of stably transduced cell lines by changing to medium containing puromycin at 2 μg/mL. The exchange media must be treated with 10% bleach in the hood for at least 30 minutes before disposal. e. Passage and expand the cells in puromycin (2 μg/mL-containing MEM medium for ~7 days, and then measure METTL3 mRNA and protein expression to determine silencing efficiency ( Figure 1 ). If necessary, continue the selection until high knockdown efficiency is achieved. Usually, the high knockdown efficiency indicates that the gene expression in the shRNA transduced cells is below 20% compared to control cells by RT-qPCR or Western blotting (see troubleshooting problem 1).

Timing: 1 week Note: All steps involving SARS-CoV-2 live virus should be performed in a BSL3 laboratory.

3. Prepare SARS-CoV-2 for infection using standard procedures for virus propagation and quantification of infectious units by plaque assay with Vero E6 cells (Harcourt et al., 2020) . We obtained SARS-CoV-2 isolate USA-WA1/2020 from BEI Resources. 4. Resuspend the control and METTL3-knockdown Caco-2 cells in complete MEM medium and seed at ~3 × 10 6 cells in one 10-cm dish or one full 6-well plate. Prepare at least triplicate dishes/wells per experimental condition. 5. Infect Caco-2 cells with SARS-CoV-2 at a multiplicity of infection (MOI) of 2 diluted in serum-free MEM medium, one hour after infection, the virus-containing medium is disposed, and infected cells are washed by DPBS once, add fresh complete MEM medium and incubate the cells at 37°C for 24 h. Collect the supernatants and then harvest the cells by addition of TRIzol. 6. Obtain the viral copy number in the supernatant by RT-qPCR analysis by using iTaq Universal SYBR Green One-Step Kit and comparison with a standard curve generated from in vitro-transcribed viral nucleocapsid (N) region ( Figure 2 ). 7. Proceed to the following Step-by-Step Method Details section for extraction and quantification of viral RNA and cellular mRNA.

Extract and purify viral RNA from cell supernatants and mRNA from infected cells

This section describes the steps for RNA extraction from supernatants and infected Caco-2 cells collected in the preceding step. Note: All steps with SARS-CoV-2 live virus-infected cells and supernatants should be performed in a BSL3 laboratory. 8. Extract viral RNA from Caco-2 culture supernatants. a. Add 30 mL TRIzol LS per 10 mL supernatant, mix by pipetting, and incubate for 5 min at 25°C.

Note: Samples can be transferred from the BSL3 laboratory after completion of this step.

The supernatant-TRIzol LS mixture can be frozen at −80°C for ≤7 days before moving on to RNA extraction.

b. Aliquot the culture supernatant/TRIzol LS mixture into 50 mL tubes at 20 mL per tube. Add 4 mL of chloroform to each tube and shake for 20 s. c. Incubate the tubes for 10 min at 25°C. d. Centrifuge the tubes at 12,000×g for 15 min at 4°C. e. Transfer the ~7ml upper phase to a fresh 50 mL tube, add 2 μL GlycoBlue, and mix. f. Add 10 mL isopropanol per tube, mix, and incubate for 10 min at 25°C .

g. Centrifuge the 50 mL tubes at 12,000×g for 15 min at 4°C. h. Remove and discard the supernatant and gently wash the RNA pellet by adding 1 mL of 75% ethanol. i. Aspirate the ethanol, air dry the RNA pellet for 5-10 min, and dissolve in 20 μL nuclease-free water. j. Perform in-column DNase I treatment at 25°C for 15 minutes and concentrate it using an RNA Clean & Concentrator-5 kit according to the manufacturer's instructions https://files.zymoresearch.com/protocols/_r1013_r1014_r1015_r1016_rna_clea n_concentrator-5.pdf k. Aliquot the RNA and store at -80°C until use.

Alternatives: RNA in the supernatants can also be extracted using a Direct-zol RNA Purification kit. c. Isolate mRNA from the 100µg purified total RNA sample using a Magnetic mRNA Isolation kit according to the manufacturer's instructions https://www.neb.com/-/media/nebus/files/manuals/manuals1550.pdf?rev=bf3077d4994b492fb81dc09 702571e84&hash=EC035147BC5AE92258976BFD95143341. Perform two rounds of polyA selection to ensure the mRNA is of high purity. d. Check the mRNA quality (e.g., Agilent TapeStation) to be sure that ribosomal RNA (rRNA) is depleted (Figure 3) .

Alternatives: rRNA depletion can also be performed using an rRNA depletion kit such as the RiboMinus Eukaryote System v2.

This section describes the steps for performing immunoprecipitation of m6A (MeRIP) from the isolated viral RNA and cellular mRNA. The steps are identical for both RNA types.

During optimization experiments, we determined that this fragmentation step can be performed on as little as 300 ng of cellular mRNA (see troubleshooting problems 2-3).

10. RNA fragmentation a. Dilute equal amounts of supernatant RNA or cellular mRNA in 9 µL nucleasefree water. J o u r n a l P r e -p r o o f h. Air dry the RNA pellet for 5 min and then dissolve in 20 μL nuclease-free water. Pause point: The RNA can be stored in -80°C for ≤7 days.

i. Measure the concentration of fragmented RNA using a Nanodrop or Qubit. j. Remove 10% of the fragmented RNA solution (2 μL) and place at −80°C for use as the "input RNA" sample. The remain ~18 μL of fragmented RNA is used for MeRIP.

The recovery rate of fragmented RNA should be >90%.

11. MeRIP of fragmented RNA a. Add 500 μL MeRIP binding buffer to the ~18 μL fragmented RNA solution and mix gently. b. Add 5 μL of anti-m6A antibody and 2.5 μL of RNase inhibitor to the sample. c. Rotate the sample at 4°C for 2 h to allow binding of the antibody to m6Amodified RNA fragments. d. For each immunoprecipitation (IP) sample, prepare 50 μL of protein A/G magnetic beads by washing twice with MeRIP binding buffer. e. Add the IP sample solution to the pre-washed magnetic beads and rotate at 4°C for 2 h. f. Collect the beads using a magnetic stand and discard the supernatant. g. Add 500 µL of MeRIP binding buffer to the magnetic beads, mix well, collect the beads using the magnetic stand, and discard the supernatant. h. Add 500µL of MeRIP wash buffer to the tube, mix well, and collect the beads with a magnetic stand, discard the supernatant. Repeat the wash twice. i. Add 50 μL of freshly prepared MeRIP elution buffer to the beads and incubate in a ThermoMixer at 25°C for 20 min. Collect the eluates. j. Repeat step i for a second elution of the beads and combine the two eluates. k. Purify RNA from the eluates using an RNA Clean & Concentrator kit according to the manufacturer's instructions https://files.zymoresearch.com/protocols/_r1013_r1014_r1015_r1016_rna_clea n_concentrator-5.pdf. Eluate the MeRIP RNA in 6 μL RNase-free water.

This section describes the steps to prepare the library for NGS from the input RNA and MeRIP RNA samples and the bioinformatics analysis of the sequencing results.

12. Prepare input and MeRIP sample libraries for NGS. a. Take out the purified input and MeRIP RNA and equalize the volume to 6 uL by adding 4 uL RNase-free water to 2 uL input RNA. b. Prepare the libraries using an Illumina TruSeq Stranded mRNA kit with the following modifications.

Note: Locate and thaw the reagents before starting the preparation.

c. Instead of the kit instructions, bring the volume of the RNA solutions up to 18 μL with FPF mix, which contains the random hexamer primers. d. Instead of repeating the fragmentation, heat the samples at 65°C for 5 min, which disrupts RNA structure and facilitates priming, and then proceed to the first-strand synthesis step. Thereafter, follow the manufacturer's instructions. https://support.illumina.com/content/dam/illuminasupport/documents/documentation/chemistry_documentation/samplepreps_tru seq/truseq-stranded-mrna-workflow/truseq-stranded-mrna-workflow-checklist-1000000040600-00.pdf e. Check the library quality, normalize, and pool the libraries for NGS. The sequencing is performed in Illumina NovaSeq 6000 instrument. The read length is 101bp pair end and the reading depth is ~50M/sample.

The library can also be prepared using an Illumina TruSeq Stranded Total RNA kit (or similar kit) with the following modifications. Instead of the kit instructions, add 8.5 μL EPH buffer to 8.5 μL of RNA sample. Instead of repeating the fragmentation, heat the samples at 65°C for 5 min to disrupt the RNA structure and facilitate priming, and then proceed to first-strand synthesis. e. Upload the BedGraph file and the bed file to view the called peaks in Integrative Genomics Viewer (Figure 4 ) (see Troubleshooting Problem 4).

14. Validate the Me-RIP-Seq findings by performing MeRIP-RT-qPCR. a. Design 4 sets of qPCR primers for the m6A-enriched nucleocapsid (N) region in SARS-CoV-2 (primers for N1-N4 are listed here: MeRIP-N1: nCoV_N1-F: 5'-GACCCCAAAATCAGCGAAAT-3', nCoV_N1-R : 5'-TCTGGTTACTGCCAGTTGAATCTG-3'; MeRIP-N2: nCoV_N2-F: CACATTGGCACCCGCAATC, nCoV_N2-R: GAGGAACGAGAAGAGGCTTG; MeRIP-N3: nCoV_N3-F: GGAACTAATCAGACAAGGAAC, nCoV_N3-R: GAAATTTGGATCTTTGTCATC; MeRIP-N4: nCoV_N4-F: ACATTCCCACCAACAGAGCC, nCoV_N4-R: CAGCACTGCTCATGGATTG). b. For negative controls, design primers to amplify SARS-CoV-2 envelope (E) gene and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which represent unmethylated viral and Caco-2 genes, respectively. For the present analysis, the primers were designed based on the location of the m6A peaks in the SARS-CoV-2 viral genome ( Figure 5A ). c. Perform MeRIP on the RNA samples as described in steps 10-11 above. In the IP step, include samples incubated with IgG control antibody equal to the amount of anti-m6A antibody (5 µg). Equalize the final volume of purified 10% input and MeRIP RNA to 6ul in RNase-free water. d. Take 1 μL of the final eluates from the MeRIP samples and 1 μL of the reserved input RNA and perform reverse transcription with an iScript cDNA synthesis kit using the following reaction conditions:

Step Temperature Time Priming 25°C 5 min Reverse transcription 46°C 40 min RT inactivation 95°C 1 min e. Dilute the cDNA 10-fold in Nuclease-free water, and prepare 10 μL PCR reaction samples as indicated below and run the samples on a LightCycler 480. J o u r n a l P r e -p r o o f Note: Multiplication by 10 corrects for the percentage of input (10%). The absolute input % value of the positive region should be >0.5 and the negative control should be <0.1. The relative value of positive m6A modified region is compared with IgG. The value of fold enrichment from positive region should be more than 5 over IgG, and the value of negative region should be about 1.

CRITICAL: At least three biological replicates should be included for each group.

The human Caco-2 stable cell lines of control and METTL3 knockdown are generated and validated by both RT-qPCR and Western blotting (Figure 1 ). The RNA from SARS-CoV-2 infected cells and supernatant are collected by adding Trizol/LS reagents. The isolated RNAs are treated with DNase I, concentrated and rRNA are depleted from the total RNAs. rRNAs are greatly depleted after rRNA depletion treatment ( Figure 3 ). After MeRIP-Seq, the reads are aligned to SARS-CoV-2 viral genome, and m6A-modified RNA peaks will be determined and visualized. When knockdown of m6A methyltransferase METTL3 is achieved, the fold enrichment of m6A signals in the C-terminal of the virus are decreased in the METTL3 knockdown cells (Figure 4 ). MeRIP-RT-qPCR is used to validate the data from MeRIP-Seq, and the RT-qPCR results showed the m6A positive (N-1, N-3, N-4) and negative modified region (E, N2) of SARS-CoV-2 genome, which is consistent with sequencing results. And in METTL3 knockdown cells, m6A signals decrease in the modified regions of SARS-CoV-2. These results confirm and validate the MeRIP-Seq results ( Figure 5 ). In summary, the expected results will show the existence of m6A modifications in SARS-CoV-2 genome, which is positively regulated by the host m6A methyltransferase METTL3.

Data are presented as the mean ± standard error (SEM) of the number of biological replicates indicated in the legends. Student's t test was used to compare group means. p < 0.05 indicates statistical significance.

If the amount of RNA and mRNA required for MeRIP-Seq or MeRIP-RT-qPCR is limiting, samples may be pooled for sequencing. We performed MeRIP of both supernatant RNA and cellular mRNA, and virions were not purified from the viral supernatant. Therefore, the results of viral RNA m6A modification should ideally be confirmed using purified virions. To validate the results of the experiment shown here, we compared the m6A signals from SARS-CoV-2 viral RNA isolated from cultures of control and METTL3-knockdown cells by both MeRIP-Seq and MeRIP-RT-qPCR. Other methods can also be applied to validate the results, including m6A mapping at individual nucleotide resolution using cross-linking and immunoprecipitation (miCLIP) (Linder et al., 2015) . 

Low viral titers and poor cell condition during transduction are the main reasons for failure of knockdown and poor cell yield. When generating the virus, ensure that the 293T cells are seeded 24 h before transfection and are in logarithmic growth phase with normal morphology before transduction. When changing the medium and collecting viral supernatants, aspirate the medium gently and avoid touching the cell layer. The optimal MOI for the target cells is best determined in pilot studies using various dilutions of virus.

Problem 2. Low amount of MeRIP RNA amount after m6A IP and RNA purification.

The amount of purified RNA is too low after MeRIP for library preparation for next-generation sequencing (NGS). The minimum RNA for library preparation should be at least 1ng (steps 8-11).

Use at least 300 ng of cellular mRNA or rRNA-depleted RNA to perform the MeRIP experiments by increasing viral infected cell numbers and total RNA amount (steps 8-11).

Recover the RNA as much as possible in each purification steps by following the instructions (steps 8-11). Combine two m6A-modified RNA eluates by using fresh prepared MeRIP elution buffer (step 11).

Problem 3. Low number of reads to align to the viral genome.

When constructing the library, the amount of cDNA and final amplified DNA may be too low for sequencing (step 12).

Increase the number of cells and/or volume of supernatant from which RNA is extracted (steps 8-10) and thus the amount of RNA available for MeRIP (step 11). When preparing the library, determine the number of PCR cycles required for a given amount of cDNA template. The number of required PCR cycles is dependent on the cDNA amount, primer-dimer ratio and other factors, usually minimum PCR cycles should be used to achieve enough amount of library for sequencing. Target about 5 × 10 7 sequencing reads per sample (step 12).

Problem 4. MeRIP-Seq data has high background noise High background noise and low signal-to-background ratio leads to poor peak calling (step 13).

For MeRIP, it is essential that the elution buffer is freshly prepared. If problems remain even with fresh elution buffer, also use freshly prepared binding buffer and wash buffer. 

Design primers that are specific for RNA regions that are positive and negative for m6A peaks according to the MeRIP-Seq results (e.g., N region and E region, respectively, in Figure 5 ). Use the same amount of IgG as the anti-m6A antibody in the IP step. Prepare all buffers fresh. Increase the input RNA amount in MeRIP experiments (step 14c) or decrease the cDNA dilution (step 14e).

Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Tariq Rana (trana@health.ucsd.edu).

This study did not generate any new or unique reagents.

The datasets generated during this study are available at GEO: GSE167075. J o u r n a l P r e -p r o o f (B) Western blot analysis of METTL3 protein in Caco-2 cells expressing control or METTL3targeting shRNA. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was probed as a loading control. These data are from the original Figures 1D and 4F in (Li et al., 2021) .

The equation and R 2 are shown. N_Sarbeco primer sets were used for qPCR (Corman et al., 2020) . Data are presented as the mean ± SEM (n=3). SARS-CoV-2 reads were aligned with STAR and peaks were called by MACS2 without removing duplicates. Blue, red, and green color indicates input viral RNA, and viral RNA extracted from supernatants of control and METTL3-knockdown cells. Bed files of the called peak regions are shown under the MeRIP track of each group. The scale of the peak density is the same for all groups. The enlarged view shows m6A signals in the 3′ end of the SARS-CoV-2 genome. These data are from the original Figure 1F in (Li et al., 2021) .

(A) Expanded view of the m6A signals in the SARS-CoV-2 genome (as in Figure 4 ) with the qPCR primer design of the N gene (N1-4) and E gene shown below.

(B) MeRIP-RT-qPCR of viral RNA extracted from SARS-CoV-2-infected Caco-2 cells expressing shControl or shMETTL3. Equal amounts of viral RNA were immunoprecipitated with control IgG antibody or anti-m6A antibody. Amplification of E and GAPDH RNA served as negative viral and Caco-2 controls, respectively. Data are presented as the mean ± SEM (n=3). * p < 0.05, * * p < 0.01, and * * * p < 0.001 by Student's t test. These data are adapted from the original Figures 1F and 1G in (Li et al., 2021) .

m6aViewer: software for the detection, analysis, and visualization of N(6)-methyladenosine peaks from m(6)A-seq/ME-RIP sequencing data

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

STAR: ultrafast universal RNA-seq aligner

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States

igv.js: an embeddable JavaScript implementation of the Integrative Genomics Viewer (IGV). bioRXiv

Fast gapped-read alignment with Bowtie 2

The Sequence Alignment/Map format and SAMtools

METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection

ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

Singlenucleotide-resolution mapping of m6A and m6Am throughout the transcriptome

Cutadapt Removes Adapter Sequences From High-Throughput Sequencing Reads

Variant Review with the Integrative Genomics Viewer

Integrative genomics viewer

Integrative Genomics Viewer (IGV): highperformance genomics data visualization and exploration

Model-based analysis of ChIP-Seq (MACS)

We thank Drs. Kristen Jepsen and Huazhen Yao of the Institute of Genomic Medicine at UCSD for help with the library preparation and sequencing. This work was supported in part by National Institutes of Health (CA177322, DA039562, DA046171, and AI125103).